Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Accenture
Argus Health
AstraZeneca
Medtronic
Harvard Business School
Cantor Fitzgerald
Dow
Baxter

Generated: November 12, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020551

« Back to Dashboard

NDA 020551 describes NIMBEX PRESERVATIVE FREE, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. Additional details are available on the NIMBEX PRESERVATIVE FREE profile page.

The generic ingredient in NIMBEX PRESERVATIVE FREE is cisatracurium besylate. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
Summary for 020551
Tradename:NIMBEX PRESERVATIVE FREE
Applicant:Abbvie
Ingredient:cisatracurium besylate
Patents:0
Pharmacology for NDA: 020551
Suppliers and Packaging for NDA: 020551
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551 NDA AbbVie Inc. 0074-4378 0074-4378-24 5 mL in 1 VIAL, SINGLE-DOSE (0074-4378-24)
NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551 NDA AbbVie Inc. 0074-4378 0074-4378-05 5 mL in 1 VIAL, SINGLE-DOSE (0074-4378-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2MG BASE/ML
Approval Date:Dec 15, 1995TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 10MG BASE/ML
Approval Date:Dec 15, 1995TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2MG BASE/ML
Approval Date:Dec 15, 1995TE:APRLD:Yes

Expired US Patents for NDA 020551

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
McKesson
Chubb
Deloitte
Covington
Boehringer Ingelheim
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.